ATP potencies and agonist-induced current responses of the indicated P2X2 receptor mutants before and after MTS treatment
| rP2X2 | MTS | EC50 (95% CI) | nH | 1 mM ATP | n |
|---|---|---|---|---|---|
| µM | Imax, µA | ||||
| rP2X2C9.348,430S | — | 8.5 (6.4–10.2) | 1.6 ± 0.3 | 54.1 ± 5.3 | 6 |
| MTSEA | 8.6 (7.9–9.5) | 1.4 ± 0.3 | 56.7 ± 4.7 | 5 | |
| MTSES | 7.9 (6.9–8.7) | 1.6 ± 0.3 | 47.6 ± 5.8 | 5 | |
| E167C-rP2X2C9.348,430S | — | 12.9 (10.9–15.3) | 1.7 ± 0.2 | 24.9 ± 4.9 | 6 |
| MTSEA | 39.6 (33.9–46.1) | 1.2 ± 0.3 | 19.9 ± 1.6 | 5 | |
| MTSES | 6.6 (5.5–8.1) | 2.3 ± 0.3 | 29.0 ± 1.8 | 5 | |
| R290C-rP2X2C9.348,430S | — | 896 (839–981) | 2.4 ± 0.3 | 3.0 ± 0.9 | 5 |
| MTSEA | 437 (411–473) | 1.8 ± 0.6 | 8.3 ± 1.0 | 6 | |
| MTSES | 1284 (1229–1343) | 2.3 ± 0.2 | 0.4 ± 0.1 | 6 |
ATP, adenosine-5’-triphosphate; CI, confidence interval; MTS, methanethiosulfonate; n, number of independent measurements; nH, Hill coefficient.